Tiziana life sciences announces additional clinical improvements in the second patient with non-active secondary progressive multiple sclerosis (spms) after eleven months of dosing with intranasal foralumab

New york, jan. 03, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the second patient (“ea2”) with non-active secondary progressive multiple sclerosis (spms) receiving intranasal foralumab has shown additional clinical improvements since their last reported improvement in september 2022. the improvements were measured by the expanded disability status scale (edss), a u.s. food and drug administration (fda) - recognized standard clinical outcome assessment that is a measure of neural network functioning, rating different measures from 1 to 10 (disability increasing with higher scores).
TLSA Ratings Summary
TLSA Quant Ranking